MERCK ZOCOR REDUCES RISK OF CORONARY DEATH BY 42%, OVERALL MORTALITY BY 30% -- SCANDINAVIAN STUDY; BMS SEES SIMILAR RESULTS IN PRAVACHOL STUDIES
Executive Summary
The use of Merck's Zocor (simvastatin) to treat coronary heart disease patients with mild to moderately high serum cholesterol levels resulted in a 42% drop in coronary deaths and a 30% reduction in overall mortality, according to the results of the Scandinavian Simvastatin Survival Study appearing in the Nov. 19 Lancet.